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Exposure of human lymphocytes and skin fibroblasts 
in vitro to a single, clinically used dose ofPUV A, i.e., 0.1 
ttg/ml of 8-methoxypsoralen (8-MOP) plus 0.9-4 J 1 cm2 of 
longwave ultraviolet radiation (UV A), lead to the for-
mation of DNA damage as determined by alkaline elu-
tion, and to chromosome aberrations and sister chro-
matid exchanges (SCE). When lymphocyte-enriched 
plasma was obtained from psoriasis patients 2 h after 
oral intake of 8-MOP and then UV A irradiated (1.8-3.6 
J/cm2) in vitro, an increased frequency of chromosome 
aberrations and SCE was observed. Normal levels of 
chromosome aberrations and SCE were found in lym-
phocytes ofpsoriasis patients after 3-30 weeks ofPUVA 
treatment in vivo. A small but statistically significant 
increase in the SCE frequency was observed in the lym-
phocytes of psoriasis patients treated for 1-6 years with 
PUV A (mean 18.0 SCE/cell) as compared with before 
PUV A (mean 15.8, p < 0.05). Skin fibroblasts of psoriasis 
patients analyzed 5 years after the start of PUV A treat-
ment showed a normal number of SCE but a high fraction 
of filter-retained DNA in the alkaline elution assay, sug-
gesting the presence of cross-linked DNA. 
Treatment of psoriasis with PUV A, i.e., oral 8-methoxypso-
ralen (8-MOP) plus long-wave ultraviolet radiation (UVA) has 
now been in use for several years. The clinical effect is well 
documented [1), whereas there is still considerable dispute 
regarding the risk for development of tumors and mutations 
[1,2]. Even though an increased incidence of malignant skin 
tumors has been reported in PUV A-treated patients [3], the 
role of PUV A for the initiation of these tumors has been 
questioned by several authors [1,4). 
8-MOP reacts with DNA dming UVA irradiation forming 
various types of DNA adducts including interstrand cross-links 
[5], and it is likely that PUV A, as many other antipsoriatic 
agents including dithranol and sunlight, exerts its main biologic 
effects by introducing damage to DNA. A variety of cytotoxic 
and genotoxic effects have been demonstrated in mammalian 
cells after exposme to clinically relevant PUV A doses, but no 
or very few such effects have been noticed in PUVA-treated 
patients [6]. 
In view of the possibly carcinogenic and mutagenic hazards 
of PUV A, it seems important to explore different genetic effects 
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of photochemotherapy in vivo, which could help to predict 
carcinogenic or mutational events. Two types of cells are con-
veniently available for this pmpose. Peripheral lymphocytes 
have a long prereplicative life span which facilitates the detec-
tion of accumulating DNA and/or chromosome damage. Skin 
fibroblasts are of interest since they receive a substan tial ac-
cumulated dose of PUV A dming extended photochemotherapy 
in vivo. In the present work we have studied DNA damage by 
use of the alkaline elution technique, and chromosom e damage 
by means of aberration and sister chromatid exch ange (SCE) 
analysis in lymphocytes and fibroblasts from PUVA-treated 
psor iasis patients during sustained photochemotherapy. The in 
vivo results are compared with the effects of PUV A treatment 
of lymphocytes and fibroblasts in vitro. 
MATERIALS AND METHODS 
Clinical PUVA Treatment 
Patients with severe psoriasis resistant to conventional treatment 
were selected. The treatment schedule was as previously described [7] 
with minor modifications. 8-MOP (0.6 mg/kg, Neo meladine, The 
Memphis Chemical Co, Cairo, Egypt, later exchanged for P uvamet, 
Draco Pharmaceut. Co, Sweden) was given orally, followed 2- 2.5 h 
later by UV A irradiation of the body surface. The treatment was 
repeated 2-5 days a week for a number of weeks depending on the 
progress of healing, after which maintenance therapy was started. 
Maintenance treatment was usually administered once a week for 2 
months. Most patients received repeated courses of PUV A 2- 4 times a 
year or cont inuous regular treatment once or twice per week. The 8-
MOP concentration was kept constant whereas the UVA dose was 
gradually increased to compensate for th e skin tanning. A comm on 
init ial UVA dose was 1.5- 3 J /cm2 to reach approximately 15-20 J /cm2 
during maintenance treatment. See Table I for individual patient data. 
Cells 
Light -sheltered and heparinized blood samples were obtained from 
healthy donors and psoriasis patients. Leukocytes plus plasma were 
isolated by centrifugation. The lymphocytes were cultivated, harvested, 
and used to make chromosome preparations for aberration and SCE 
analysis as described previously [7,8]. In some cases th e cells were 
subjected to in vitro experiments before th e setting of the cultures (see 
below). 
Fibroblast cultures were establish ed from skin biopsies of psoriasis 
patients and from healthy donors. The cultw-es were kept in Eagle's 
minimal essential medium (MEM) with or without 20 p.M Hepes buffer 
(when Petri dish or Falcon flask was used, respectively) supplemented 
with 10% fetal calf serum, 150 p.g/ ml of streptomycin, and 85 !Lg/ ml of 
benzylpenicillin. The cells of th e psoriasis patients were analyzed for 
the presence of SCE and/ or DNA damage within 3- 6 weeks after the 
skin biopsy, i.e., as soon as a confluent cell layer was obtained in 3 25-
cm2 Falcon flasks. 
93 
UV A Irradiation 
Several clinical UV A sources, emitting mainly 320-380 nm with 
maximum intensity at 365 nm, were used. The intensity at the body 
surface was regularly measw-ed with a Hewlett Packard radiant flux 
meter or with a PUVA meter (H. Waldmann Werk fur Lichttechnik). 
The sow-ces in use dw-ing the fu·st years of this study had an intensity 
of 3 mW /cm2 whereas the presently used lamps emit 15 mW /cm2 . 
In most of the in vitro experiments 2 Philips TL 20 W / 08 bulbs, 
mounted at a distance of 10 em from the cells, were used. The radiation 
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TABLE I. Medical history data of the psoriasis patients treated with PUVA forl-6 years before analysis of DNA and chromosome damage 
Year of Cigarettes per 
Earlier psoriasis therapy PUVA treatment 
Case Sex birth day Arsenic Metho- Hydroxyurea Dithranol Tar Total Total dose trexate Years number (J /cm2 ) 
1 M 1941 0 + + 1975-1980 230 1970 
2 M 1946 <10 + + 1975-1977 94 310 
3 F 1924 0 +" 1975-1978 64 370 
4 M 1944 >10 + 1975-1976 110 370 
5 F 1953 0 + 1975-1976 72 260 
6 M 1937 0 + + + 1977-1980 175 1070 
7 F 1921 0 +" 1976-1980 147 1250 
8 M 1942 0 + + 1976-1977, 1980 76 520 
9 M 1910 <10 +" + + 1977-1980 179 1740 
10 F 1950 >10 + + 1974-1980 378 1860 
11 F 1954 <10 + 1976-1980 llO 1720 
12 F 1942 0 + + 1977-1980 155 1920 
"Three times in the 1930s (case 9) and a few treatments in the 1940s (case 3). 
"During 10 weeks 1975-1976. 
was filtered thTough plain window glass in the alkaline elut ion experi-
ments. Determinations by an EG & G 580/585 spektroradiometer 
showed the total intensity at the cell level to be 1.24 m WI cm2 in the 
range of 300-400 nm, and only 0.1% of the intensity was of a wavelength 
under 320 nm (0.7% without glass ftlter). The radiation energy peaked 
at 350-360 nm and stretched up into the visible fie ld. 
In the experiments of Fig 3 with defined concentrations of 8-MOP, 
the UVA soUTce was a Black-Ray B100A (Ultraviolet Products) (5 
mW / cm2). The Falcon flasks containing the cell suspensions were found 
to tmnsmit 100% of the radiation. According to the spektroradiometer 
less than 1% of the intensity was below 320 nm. 
Analysis of Chromosome Aberrations 
In 20 patients chromosome analysis of peripheral lymphcoytes was 
made before and after 3-30 weeks of treatment. From 10 of the 20 
patients, a blood sample was also taken on 2 additional occasions. The 
fu·st sample was obtained on the day before the start of treatment. The 
second sample was obtained on the first day of treatment, 2 h after 8-
MOP intake but before UVA. This sample was divided into 3 portions. 
Two portions were irradiated in vitro with 2 different UV A doses using 
a clinical UV A source, whereas the third portion served as an unirra-
diated control, as described previously [8]. The third sample was 
obtained on the second day of treatment before 8-MOP was given, and 
the fourth sample 3-30 weeks later. Conventional lymphocyte cultuTes 
with phytohemagglutinin (PHA) were set up, and the harvest was done 
50 h later. Staining with Giemsa and scoring of aberrations were carried 
out as_ described previously [7]. When possible, 100 cells were analyzed, 
but in a minority of cases fewer cells were scored due to lack of mitoses 
or bad preparations. The in vitro experiments were carried out as 
described in detail previously [7]. 
SCE Analysis 
SCE analysis in lymphocytes from in vivo treated patients was 
carried out as described previously [8). Freshly collected lymphocytes 
from healthy donors were used· for in vitro experiments. The cells 
contained in growth medium in 25-cm2 Falcon flasks were exposed to 
8-MOP (Sigma, St Louis, Missotll"i; 0.025-0.25 mg/ rnl dissolved in 
ethanol) for 0.5-1 h at 37°C in the dark before exposUTe to various 
doses of UVA at room temperature. The cells were then washed with 
Hanks' balanced salt solution and resuspended in fresh cultUTe medium 
containing PHA and 100 !lM of BrdUrd. After a cultivation time of 74 
h in the dark, the cells were fixed, subjected to hypotonic treatment, 
and stained as described previously [8]. The SCE frequency was scored 
at high magnification in the light microscope. A minimum of 20 cells 
were scored from each culture. Controls were handled in the same way 
as the treated cultures except for PUV A exposme (receiving only the 
solvent, ethanol, which did not exceed 0.5% in any of the cultures). Skin 
fibrob lasts from in vivo treated patients were cultivated in 25-cm2 
Falcon flasks for 48 h in the presence of 10 !lM of BrdUrd. Cells from 
healthy donors cultivated in parallel were used as controls. Slide 
preparation and SCE analysis were as described above for lymphocytes. 
Alkaline Elution 
Skin fibroblasts from psoriasis patients and from healthy donors 
were grown on 1-cm2 glass discs at the bottom of a Petri dish containing 
Eagle's MEM. Labeling of the cells with ["H)-thymidine and PUV A 
treatment in vitro were as described previously [9]. 
The alkaline elution method was in principle adopted from Kohn 
[10] and was modified as described in detail previously [9,11]. About 
10" skin fibroblasts were lysed with a detergent solution on a 2-!lm pore 
size Millipore filter mounted in a light-sheltered filter holder. Elution 
of DNA was accomplished by pumping a tetraethylammoniumhydrox-
ide solu tion (Merck, Darmstadt, West Germany) (pH 12.6) through the 
ftlter at a speed of about 50 p.i/min. Fractions were collected every 2 h 
for a total time of 10 h. The amount of radioactivity in the fractions 
and on the filter was determined by scintillation counting. 
RESULTS 
DNA Damage in Skin Fibroblasts 
Skin fibroblasts from normal, healthy donors were exposed 
in vitro to PUVA (0.1 !Lg/ml of 8-MOP plus 3 J/cm2 of UVA), 
to UVA alone (3 J/cm2), or were left untreated. The resulting 
alkaline elution curves are shown in Fig 1. Approximately 80% 
of the DNA from untreated cells remained on the filter after an 
elution time of about 10 h. The UV A-irradiated cells showed a 
faster elution rate, leaving about 40% of the DNA on the filter 
after the same time period. This indicates that UV A induces 
DNA strand breaks [11]. PUVA-treated cells showed an elution 
rate in between the UVA-irradiated cells and the untreated 
control cells, which indicates that PUVA superimposes DNA 
cross-links on the UVA-induced breaks. The intermediary elu-
tion rate observed in the PUV A-treated cells is the net effect of 
an increased elution rate due to strand breaks and a decreased 
elution rate due to cross-links [9,10]. The elution rate was not 
affected by treatment of the cells with 8-MOP in the absence of 
UVA radiation (not shown). 
Skin biopsies were taken from 3 psoriasis patients 5 years 
after the start of PUV A treatment. Ordinary fibroblast cultures 
were set up and analysis of DNA damage was made as soon as 
a sufficient number of cells had been obtained. DNA damage 
was analyzed by alkaline elution after the cells had been culti-
vated for a few days in the presence of [3H]-thymidine in order 
for their DNA to become labeled. Immediately prior to the 
elution procedure, one portion of the fibroblasts was irradiated 
in vitro with 1.1 J/cm2 of UVA while the rest of the cells were 
left untreated. This UV A exposure was used in an attempt to 
convert preexisting 8-MOP monoadducts into cross-links [9], in 
order to facilitate their detection with this technique. 
Fig 2 shows the elution curves of fibroblasts from the 3 
psoriasis patients (full lines) and 2 representative, healthy con-
trol subjects (broken lines) . The light-protected cells (-UV A) 
as well as the UV A irradiated cells from the psoriasis patients 
showed unusually low elution rates, and all curves were in fact 
located at or below the extreme of the control range based on 
more than 20 determinations in normal cells from 4 different, 
healthy donors. This result is rather surprising in suggesting 
that PUV A-induced DNA damage, or damage introduced by 
earlier psoriasis therapy, may be retained in skin-derived fibro-
blasts during several cell cycles in vivo and in vitro. 
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Sister Chromatid Exchange 
The effect of PUV A treatment in vitro on the SCE frequency 
in lymphocytes from normal donors is shown in Fig 3a (solid 
lines). Cells irradiated with UVA (1-3.6 J / cm2 ) in the presence 
of 0.1 J.Lg/ml of 8-MOP showed a considerable increase of SCEs, 
while 0.01 J.Lg/ml of 8-MOP caused a smaller but still significant 
increase. 8-MOP or UVA alone did not affect the SCE frequency 
(not shown). The increase of SCE in lymphocytes from blood 
taken from psoriasis patients 2 h after oral intake of 8-MOP 
and irradiated with UV A in vitro was found to be intermediate 
between the effects seen at 0.1 and 0.01 J.Lg/ml of 8-MOP (Fig 
3a, columns) [8]. 
The frequency of SCE in lymphocytes of PUVA-treated 
psoriasis patients is shown in Table II. In 5 patients (group A), 
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FIG 2. Alkaline elution curves of DNA 
from skin fibroblasts of 3 PUVA-treated 
psoriasis patients (cases no. 2, D •; 4, 0 
e; and 9, 0 + in Table I) and 2 repre-
sentative untreated healthy controls (6 
• and \7 '9') . Open symbols represent 
cells that were OVA-irradiated (1.1 J / 
cm2) in vitro immediately prior to the 
elution procedure; closed symbols cells 
that were protected from UV A and visi-
ble light. 
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the SCE frequency was analyzed before as well as 5 years after 
initiation of PUV A therapy. In these patients the SCE fre-
quency was slightly higher after 5 years than it was before 
PUVA (p < 0.1, paired t-test) and after 3- 30 weeks of PUVA 
(p < 0.025, paired t-test). All but 1 subject in group A showed 
a higher SCE value 5 years after the start of PUV A than before 
treatment. The remaining subjects in Table II fall into two 
patient groups. One group (C) was followed with analysis of 
SCE prospectively over 3-30 weeks as reported previously [8], 
while the patients of the other group (B) were analyzed only 
after 1- 6 years ofPUVA treatment. The numbers of SCE before 
and after 3-30 weeks of therapy were within the range found in 
normal subjects in our laboratory [12], whereas the mean SCE 
frequency of all patients studied after 1- 6 years of treatment 
was significantly increased as compared to that of all patients 
studied before PUVA therapy (p < 0.05, t-test) . The small 
decrease in SCE frequency during the first 3-30 weeks ofPUVA 
is not statistically significant [8]. 
These results then suggest that sustained, clinical PUV A 
treatment may indeed give rise to a detectable level of SCE 
inducing damage in peripheral lymphocytes provided that suf-
ficient time is allowed for the damage to accumulate or become 
modified in vivo. 
Table III shows the frequencies of SCE in fibroblasts cultured 
from skin biopsies of 4 psoriasis patients 5 years after initiation 
of PUVA therapy. No difference was noted between fibroblasts 
derived from these psoriasis patients and fibroblasts from 
healthy donors. 
Chromosome Aberrations 
In a previous report [7] it was shown that treatment of human 
lymphocytes in vitro with PUV A gives rise to chromosome 
~berrations, mainly breaks of the chromatid type. Although no 
mcrease was observed at the lower PUV A dose used (0.1 J.Lg/ ml 
of 8-MOP and 1.05 J/cm2 of UVA) there was a 4-fold increase 
of chromosome aberrations at the higher UVA dose (4.2 J/cm2) 
(Fig 3b, solid line), which indicates that chromosome aberration 
analysis is a less sensitive assay for PUV A-induced chromosome 
damage than the SCE analysis. Nevertheless, it was found that 
UV A irradiation of lymphocytes taken from psoriasis patients 
2 h after oral intake of 8-MOP caused an increase in aberrations 
(p < 0.005, analysis of variance; p < 0.001, t-test of the higher 
UVA dose) (Fig 3b, columns). This finding indicates that the 
therapeutic 8-MOP concentration in peripheral blood combined 
in vitro with a therapeutic UV A dose gives rise to a UV A dose-
dependent increase in chromosome aberrations. The types of 
aberrations that showed an increase were chromatid breaks and 
rearrangements, whereas the frequency of gaps was not signifi-
cantly different (p > 0.25) from that in untreated cells. 
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TABLE II. SCE frequencies in lymphocytes from psoriasis patients 
treated during different time periods with P UV A 
Psoriasis patients SCE/cell" 
After 3-30 After 1-6 years Group Casesb BeforePUVA weeks of 
PUVA ofPUVA 
A 1-5 15.2 ± 2.4 13.3 ± 3.0 17.6 ± 2.2 
B 6-12 18.2 ± 2.9 
c 13-21 16.0 ± 2.5 14.7 ± 4.9 
Total 15.8 ± 2.4 14.2 ± 4.3 18.0 ± 2.6 
"Group mean (± SD) calcu lated from individual means based on 20 
cells in each subject. 
"For additional clinical data see Table I. Cases 1- 5 and 13-21 were 
studied in 1975-1976 before PUVA as well as after 3-30 weeks of PUV A 
treatment. Cases 1- 5 and 6-12 were stuclied in 1980 after 1-6 years of 
PUVA. 
TABLE III. The frequency of SCE/cell in shin fibroblasts from 4 
P UV A· treated psoriasis patients 
Patients Case" Healthy donors 
11.4 1 9.5 
8.9 2 10.4 
10.6 4 10.0 
11.7 5 10.7 
Mean± SD 10.7 ± 1.3 10.2 ± 0.5 
" For patient data see Table I. 
TABLE IV. Frequencies of chromosome gaps and aberrations per 
100 lymphocytes from psoriasis patients before and during P UV A 
treatment 
Chromosome aberrations '' 
Gaps Rear- Number of 
Breaks range- Total patients 
ments 
Before PUVA 3.7 2.3 1.2 3.4 20 
Second day of 1.9 1.8 0.6 2.4 10 
treatment 
After 3-30 weeks of 2.2 1.7 0.9 2.6 20 
treatment 
"Gaps and breaks include lesions of the chromatid and chromosome 
type respectively. Rearrangements include various types of chmmatid 
and chromosome exchanges. 
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FIG 3. The frequency of SCE (a) and 
chromosome aberrations (b) in human 
lymphocytes exposed to 8-MOP in vivo 
(columns ) or in vitro (solid lines ), and 
irradiated with UVA in vitro. Cells ex-
posed to 8-MOP in vivo were obtained 
from psoriasis patients 2 h after oral 
intake of the regular clinical dose of 8-
MOP, i.e., immecliately before clinical 
UV A irradiation. The cells were irradi-
ated in vitro with UV A with indicated 
doses. The columns show the mean fre -
quency of SCE (a) in 17 donors [18] and 
chromosome aberrations (b) in 10 do-
nors. Bars indicate the SE. Cells from 
healthy, nonpsoriatic donors were used 
for treatment with various doses of 8-
MOP and UVA in vitro. The average 
frequency of SCE (a) and chromosome 
aberrations (b) was determined after 
treatment with 0.01 llg/ml (V'-- \7) or 
0.1 llg/ rnl (6--6) of 8-MOP in 2- 4 
separate experiments. For further details 
see Materials and M ethods. 
The frequency of chromosome aberrations was studied in 20 
patients before PUVA, on the second day of treatment, as well 
as after 3-30 weeks of intensive PUVA treatment (Table IV). 
All the individual values recorded were within the range found 
in normal subjects in this laboratory (7,13]. In 10 patients the 
individual aberration frequency was lower than before treat-
ment, in 9 patients the frequency was higher after treatment, 
and in 1 patient the frequency was not changed. Analysis of 
variance (one-way classification) did not show any difference in 
any of the various types of aberrations between the different 
stages of treatment (p > 0.25). Therefore, no evidence was 
obtained that PUV A treatment in vivo gives rise to a detectable 
increase in the number of aberrations in peripheral lymphocytes 
during this relatively short period of treatment. In addition, the 
results gave no evidence that previous non-PUVA treatment 
may have caused an increased frequency of aberrations, since 
the values recorded before treatment were not different from 
those in healthy controls. 
No correlation, positive or negative, was found between the 
frequency of SCE and chromosome aberrations in the 14 pa-
tients where the frequencies of both of these parameters were 
followed during the initial 3-30 weeks of PUV A treatment. 
DISCUSSION 
The ability of PUV A to damage DNA is well documented 
[5,6]. The aim of the present study has been to find out whether 
in vivo induced genotoxic effects are detectable during long-
term photochemotherapy of psoriasis. To determine whether 
the presently applied techniques are well enough suited for this 
purpose, optimal experimental conditions in vitro were used in 
combination with a PUV A dose estimated to be of clinical 
relevance. 
The clinical serum concentration of 8-MOP at the time of 
UV A irradiation is reported to vary from 0.004 to 4 }Lg/ rnl with 
most values close to 0.1 }Lg/ml (14]. Animal experiments indicate 
that the 8-MOP concentration of the skin is similar to that of 
the blood [15]. The average UVA dose during maintenance 
therapy is about 10 J/cm2, while the initial doses are about 2 J / 
cm
2 [16- 19]. Since up to 40% of the UVA reaches the skin blood 
vessels and the dividing cells of the skin [20], doses of 0.1 JLg/ ml 
of 8-MOP plus 1-4 J/cm2 of UVA were chosen for the in vitro 
experiments to represent clinically significant PUV A doses. 
The results presented in this work show that treatment of 
human lymphocytes in vitro with clinical PUV A doses gives 
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rise to an increased frequency of SCE and chromosome aber-
rations. Similar results have been obtained in other work [7,8, 
21,22). DNA cross-linking by clinical doses of PUVA was re-
cently demonstrated in human transformed lymphoblasts [21]. 
As shown in the present work, both DNA breaks (due to UV A 
itself) and DNA cross-links, as determined by alkaline elution, 
are induced in skin fibroblasts by treatment in vitro with a 
clinically used PUV A dose. These results ru·e in agreement with 
previous observations [9,11]. In conclusion, the results of this 
and other work present convincing evidence of PUVA-induced 
genotoxic effects in human cells in vitro. 
In contrast, the possible genotoxic effects of PUV A treatment 
in vivo are much less obvious. The frequency of SCE and 
chromosome aberrations in the lymphocytes of the psoriasis 
patients did not change during the first 3-30 weeks of PUV A 
treatment and did not differ from the corresponding frequencies 
in groups of untreated healthy controls studied previously 
[7,8,13). This and other similar observations (e.g., [7,23]) may 
be explained by relatively short treatment time in these earlier 
studies and by the fact that the lymphocytes are exposed to 
only about 1-5% of the skin surface UV A dose [16]. Even if the 
SCE and clu·omosome aberration frequencies increase linearly 
with the UV A dose without any sign of a dose threshold (as 
indicated by Fig 3), each lymphocyte will probably be exposed 
in vivo to such a small PUV A dose that a very lru·ge number of 
cells need to be scored in order to demonstrate an increase. 
Nevertheless, the present finding of an increased SCE frequency 
in the peripheral lymphocytes of psoriasis patients after 1-6 
years of PUV A treatment indicates that some type of damage 
is induced and accumulated dming several years in vivo, and 
may be demonstrated by a sensitive technique. 
Skin cells are exposed to a manyfold stronger genotoxic 
influence from PUV A than are the blood cells. The skin fibro-
blasts from PUV A-treated patients were found to have a normal 
SCE frequency, but a higher than normal filter retention of 
DNA dming alkaline elution, indicating the presence of an 
increased amount of cross-linked DNA. As DNA cross-links are 
highly cytotoxic and probably disturb the separation of the 
DNA strands dming replication, it may seem contradictory that 
a technique involving several rounds of replication in between 
PUV A exposure and analysis of DNA damage detects this type 
of DNA damage. However, DNA interstrand cross-links have 
been visualized by electron microscopy in epidermal and, to a 
lesser extent, in dermal cells from healthy, untreated human 
donors [24]. This finding may indicate that cross-links do not 
necessarily inhibit cellular proliferation. In fact, a theoretical 
model including replicative bypass of DNA cross-links has been 
put forward [25], suggesting that cross-links can be conserv&d 
in replicating cells. 
The normal frequency of SCE in skin fibroblasts from in vivo 
treated patients indicates that SCE-inducing lesions do not 
accumulate in smviving and dividing skin cells. A continuous 
elimination of such lesions, via DNA repair or selection against 
severely damaged cells, may be of importance, since a correla-
tion between SCE induction and mutagenicity has been shown 
for some agents [26). In contrast to skin fibroblasts, lympho-
cytes are not subjected to the same selection pressme, since 
very few of them replicate their DNA and divide before they 
are cultivated in order to be analyzed for clu-omosome changes. 
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